Nascent Biotech (NBIO) 10-Q 12 Aug 21 2022 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Jun. 30, 2021	Aug. 11, 2021
Cover [Abstract]
Entity Registrant Name	NASCENT BIOTECH INC
Entity Central Index Key	0001622057
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Current Reporting Status	Yes
Document Period End Date	Jun. 30, 2021
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Entity Ex Transition Period	false
Entity Common Stock Shares Outstanding		107,728,175
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes
Entity File Number	000-55299
Entity Incorporation State Country Code	NV
Entity Tax Identification Number	46-5001940
Entity Address Address Line 1	623 17th Street Suite 4
Entity Address State Or Province	FL
Entity Address Postal Zip Code	32960
City Area Code	612
Local Phone Number	961-5656
Entity Address City Or Town	Vero Beach

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2021	Mar. 31, 2021
Current assets:
Cash	$ 268,835	$ 1,435
Accounts receivable	0	750,000
Prepaid	7,038	0
Total current assets	275,873	751,435
Total assets	275,873	751,435
Current liabilities:
Accounts payable and accrued liabilities	614,427	636,831
Convertible note- net of discount	52,655	161,736
Derivative liability	137,574	302,156
Due to related parties	55,500	123,217
Deferred revenue	250,000	0
Total current liabilities	1,110,156	1,223,940
Total liabilities	1,110,156	1,223,940
Commitments and contingencies	0	0
Stockholders' deficit:
Preferred stock, $0.001 par value, 50,000,000 authorized, none and 54,130 issued and outstanding. respectively	0	54
Common stock, $0.001 par value; 500,000,000 authorized, 107,728,175 and 104,834,083 issued and outstanding, respectively	107,728	104,834
Additional paid-in capital	17,859,481	17,774,023
Accumulated deficit	(18,801,492)	(18,351,416)
Total stockholders' deficit	(834,283)	(472,505)
Total liabilities and stockholder' deficit	$ 275,873	$ 751,435

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2021	Mar. 31, 2021
Stockholders' deficit
Preferred stock, shares par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	0	54,130
Preferred stock, shares outstanding	0	54,130
Common stock, shares par value	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	107,728,175	104,834,083
Common stock, shares outstanding	107,728,175	104,834,083

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Operating expenses:
Consulting	$ 162,813	$ 359,815
General and administrative expense	224,790	57,781
Research and development	55,206	133,732
Loss from operations	(442,809)	(551,348)
Other income (expense):
Interest income	6	0
Change in fair value	164,582	438,567
Gain on debt settlement	5,000	0
Financing costs	(66,150)	(3,000)
Original interest discount	(107,199)	0
Interest expense	(3,506)	(88,190)
Total other income (expense)	(7,267)	347,337
Net loss	$ (450,076)	$ (203,971)
Net loss per share, basic and diluted	$ 0	$ 0
Weighted average number of shares outstanding, basic and diluted	107,064,811	47,661,141

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS DEFICIT (Unaudited) - USD ($)	Total	Preferred Stock	Common Stock	Additional Paid-In Capital	Retained Earnings (Accumulated Deficit)
Balance, shares at Mar. 31, 2020		60,000	44,890,262
Balance, amount at Mar. 31, 2020	$ (2,875,704)	$ 60	$ 44,890	$ 13,916,995	$ (16,837,649)
Common stock issued for related parties for service, shares			2,007,000
Common stock issued for related parties for service, amount	190,915	0	$ 2,007	188,908	0
Common stock issued for AP- related parties, shares			13,831,101
Common stock issued for AP- related parties, amount	1,387,872	0	$ 13,831	1,374,041	0
Common stock issued for AP settlement, shares			35,715
Common stock issued for AP settlement, amount	5,000	0	$ 36	4,964	0
Common stock issued for service, shares			677,000
Common stock issued for service, amount	85,440	$ 0	$ 677	84,763	0
Common stock issued for preferred shares, shares		(60,000)	1,352,529
Common stock issued for preferred shares, amount	13,011	$ (60)	$ 1,354	11,717	0
Net loss	(203,971)	0	$ 0	0	(203,971)
Balance, shares at Jun. 30, 2020			62,793,607
Balance, amount at Jun. 30, 2020	(1,397,437)	$ 0	$ 62,795	15,581,388	(17,041,620)
Balance, shares at Mar. 31, 2021		54,130	104,834,083
Balance, amount at Mar. 31, 2021	(472,505)	$ 54	$ 104,834	17,774,023	(18,351,416)
Common stock issued for AP- related parties, shares			307,010
Common stock issued for service, shares			50,000
Common stock issued for service, amount	5,250		$ 50	5,200	0
Common stock issued for preferred shares, shares		(54,130)	1,968,363
Common stock issued for preferred shares, amount	0	$ (54)	$ 1,968	(1,914)	0
Net loss	(450,076)	0	$ 0	0	(450,076)
Common stock issued to related parties, shares			568,719
Common stock issued to related parties, amount	59,716	0	$ 569	59,147	0
Common stock issued for AP- related parties, amount	23,332	0	$ 307	23,025	0
Balance, shares at Jun. 30, 2021			107,728,175
Balance, amount at Jun. 30, 2021	$ (834,283)	$ 0	$ 107,728	$ 17,859,481	$ (18,801,492)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	3 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flows from operating activities:
Net loss	$ (450,076)	$ (203,971)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation - related parties	59,716	190,915
Stock-based compensation	5,250	85,440
(Gain) loss in fair value of derivative liability	(164,582)	(438,567)
Change in discount expense	173,349	72,435
Changes in operating assets and liabilities:
Accounts receivable	750,000	0
Accounts payable and accrued expenses	(84,329)	108,437
Deferred revenue	250,000	0
Prepaid	(7,038)	0
Due to related parties	(44,385)	132,525
Net cash provided by (used in) operating activities	487,905	(52,786)
Cash flows from financing activities:
Repayment of convertible notes	(220,500)	0
Proceeds from notes payable	0	50,000
Net cash provided (used) by financing activities	(220,500)	50,000
Net increase (decrease) in cash	267,405	(2,786)
Cash -beginning of year	1,434	3,218
Cash -end of period	268,839	432
SUPPLEMENT DISCLOSURES:
Interest paid	15,055	0
Income taxes paid	0	0
Non Cash Transactions
Common stock issued for conversion of preferred shares	1,968	13,011
Common stock issued for accrued expenses- related party	23,332	1,387,872
Common stock issued for accounts payable	$ 0	$ 5,000

ORGANIZATION AND NATURE OF OPER

ORGANIZATION AND NATURE OF OPERATIONS	3 Months Ended
	Jun. 30, 2021
ORGANIZATION AND NATURE OF OPERATIONS
NOTE 1 - ORGANIZATION AND NATURE OF OPERATIONS	NOTE 1 – ORGANIZATION AND NATURE OF OPERATIONS Nascent Biotech, Inc. (“Nascent” or the “Company”) was incorporated on March 3, 2014 under the laws of the State of Nevada. The Company is actively developing Pritumumab for the treatment of brain cancer and pancreatic cancer. Nascent is also actively researching other cancers that have a high probability of benefiting from the therapeutic effects of Pritumumab because they share a common target. Pritumumab has shown to be very effective at low doses in previous clinical studies in Japan. Nascent is a pre-clinical stage biopharmaceutical company that focuses on biologic drug candidates that are preparing for initial clinical testing for the treatment of brain and pancreatic cancer. On March 31, 2017, the Company filed its IND submission with the United States Food and Drug Administration (FDA) for clearance to begin Phase I clinical trials. On December 7, 2018, the Company received a letter from the FDA allowing it to use a specific lot of drug substance to begin phase 1 clinical trials. On March 15, 2021, the Company opened phase1 clinical trials.

BASIS OF PRESENTATION

BASIS OF PRESENTATION	3 Months Ended
	Jun. 30, 2021
BASIS OF PRESENTATION
NOTE 2 - BASIS OF PRESENTATION	NOTE 2- BASIS OF PRESENTATION The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles. The Company has elected a fiscal year ending on March 31. The accompanying unaudited interim consolidated financial statements of the Company for the three months ended June 30, 2020 and 2021 have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information in accordance with Securities and Exchange Commission and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s annual report on Form 10-K for the year ended March 31, 2021. In the opinion of management, the unaudited financial statements have been prepared on the same basis as the annual financial statements and reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the financial position and the results of operations for the interim periods presented herein. The results of operations for the interim periods are not necessarily indicative of the results to be expected for any subsequent quarters or for an entire year. Recent Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases. The main provisions of ASU No. 2016-02 require management to recognize lease assets and lease liabilities for all leases. ASU 2016-02 retains a distinction between finance leases and operating leases. The classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria for distinguishing between capital leases and operating leases in the previous release’s guidance. The result of retaining a distinction between finance leases and operating leases is that under the lessee accounting model, the effect of leases in the statement of comprehensive income and the statement of cash flows is largely unchanged from previous U.S. GAAP. The amendments in this ASU are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures. Basis of Presentation The Company computes net loss per share in accordance with ASC 260, Earnings per Share We have identified the conversion features of certain of our convertible notes payable as derivatives. We estimate the fair value of the derivatives using the Black-Scholes pricing model. We estimate the fair value of the derivative liabilities at the inception of the financial instruments, at the date of conversions to equity and at each reporting date, recording a derivative liability, debt discount, and a gain or loss on change in derivative liabilities as applicable. These estimates are based on multiple inputs, including the market price of our stock, interest rates, our stock price volatility and variable conversion prices based on market prices as defined in the respective agreements. These inputs are subject to significant changes from period to period and to management's judgment; therefore, the estimated fair value of the derivative liabilities will fluctuate from period to period, and the fluctuation may be material. Revenue recognition In April 2016, the FASB issued ASU 2016–10 Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing. The amendments in this Update do not change the core principle of the guidance in Topic 606. Rather, the amendments in this Update clarify the following two aspects of Topic 606: identifying performance obligations and the licensing implementation guidance, while retaining the related principles for those areas. Topic 606 includes implementation guidance on (a) contracts with customers to transfer goods and services in exchange for consideration and (b) determining whether an entity’s promise to grant a license provides a customer with either a right to use the entity’s intellectual property (which is satisfied at a point in time) or a right to access the entity’s intellectual property (which is satisfied over time). The amendments are intended to render more detailed implementation guidance with the expectation to reduce the degree of judgement necessary to comply with Topic 606. ASC Topic 606 prescribes a new five-step model entities should follow in order to recognize revenue in accordance with the core principle. These five steps are: 1. Identify the contract(s) with a customer. 2. Identify the performance obligations in the contract. 3. Determine the transaction price. 4. Allocate the transaction price to the performance obligations in the contract. 5. Recognize revenue when (or as) the entity satisfied the performance obligations. The Company implemented the transition using the modified retrospective method of transition. The funds are not earned on milestones that have not been reached per the contract. Based on the cut off treatment of the recognition of revenue per the milestones specific to the license agreements, the Company has determined that there are no adjustments in the value of the revenue recognized from these contracts. The Company has one revenue stream, which is the milestone payments of the license agreement with BioRay Pharmaceutical which is not earned or billed until the milestone per the agreement is met. Accounts receivable Accounts receivable are carried at face value less any provisions for uncollectible amounts. Accounts receivable are receivables from a license agreement. No allowance for bad debt was considered necessary for the three months ended June 30, 2021 and 2020, respectively. Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, accounts payable and accrued expenses and shareholder loans. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. Financial assets and liabilities recorded at fair value in our condensed consolidated balance sheets are categorized based upon a fair value hierarchy established by GAAP, which prioritizes the inputs used to measure fair value into the following levels: Level 1– Quoted market prices in active markets for identical assets or liabilities at the measurement date. Level 2– Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable and can be corroborated by observable market data. Level 3– Inputs reflecting management’s best estimates and assumptions of what market participants would use in pricing assets or liabilities at the measurement date. The inputs are unobservable in the market and significant to the valuation of the instruments. A financial instrument’s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The following table summarizes the change in the fair value of the derivative liabilities during the three months ended June 30, 2021: Fair value as of March 31, 2021 $ 302,156 Additions at fair value - Transfers in (out) of Level 3 - Change in fair value (164,582 ) Fair value as of June 30, 2021 $ 137,574

GOING CONCERN

GOING CONCERN	3 Months Ended
	Jun. 30, 2021
GOING CONCERN
NOTE 3 - GOING CONCERN	NOTE 3 – GOING CONCERN The Company’s consolidated financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has a working capital deficit and has incurred losses from operations. The Company has no revenue to cover its operating costs and the Company will incur additional expenses in the future developing their product. These factors raise substantial doubt about the company’s ability to continue as a going concern. The Company engages in research and development activities that must be satisfied in cash secured through outside funding. The Company may offer noncash consideration and seek equity lines as a means of financing its operations. If the Company is unable to obtain revenue producing contracts or financing or if the revenue or financing it does obtain is insufficient to cover any operating losses it may incur, it may substantially curtail or terminate its operations or seek other business opportunities through strategic alliances, acquisitions or other arrangements that may dilute the interests of existing stockholders. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	3 Months Ended
	Jun. 30, 2021
RELATED PARTY TRANSACTIONS
NOTE 4 - RELATED PARTY TRANSACTIONS	NOTE 4 – RELATED PARTY TRANSACTIONS On September 1, 2015, the Company entered five-year employment contracts with three of its officers and directors. One of the officers and director resigned as of September 30, 2020. Under the terms of the agreements the Company issued shares of common stock to the officers and directors equaling 11% of the outstanding shares of the Company as of the date of the contracts. As additional future shares are issued, the officers and directors are entitled to additional shares so their aggregate ownership percentage remains at 11% of the outstanding shares of the Company. The following table sets forth the shares earned under these contracts for the two active officers as of June 30, 2021: Officer and Director Initial Share Awards Under the Contracts Additional Shares Earned to Maintain Ownership Percentage Total Shares Earned President 1,028,910 7,177,269 8,206,179 Chief Financial Officer 617,346 3,821,223 4,438,569 Total 1,646,256 10,998,492 12,644,748 As of June 30, 2021, the Company had $55,500 due to officers and directors. On September 1, 2020, the Company entered five-year compensation agreements with two of its officers and directors. Under the terms of the agreements the Company issued shares of common stock to the officers and directors equaling 18% of the outstanding shares of the Company as additional future shares are issued. The officers and directors are entitled to additional future shares so their aggregate ownership percentage remains at 18% of the future outstanding shares of the Company Officer and Director Fiscal Year Annualized Compensation Being Paid President $ 250,000 Chief Financial Officer $ 180,000 Total $ 430,000 During the three months ended June 30, 2020 three officers and directors were issued 2,007,000 shares of common stock with a value of $190,915 for service. During the three months period ended June 30, 2020 three officers of the Company converted $1,387,872 of accrued compensation into 13,831,101 shares of common stock of the Company. During the three months ended June 30, 2021 three officers and directors were issued 568,719 shares of common stock with a value of $59,716 for service. During the three months period ended June 30, 2021 a director of the Company converted $23,332 of accrued compensation into 307,010 shares of common stock of the Company.

EQUITY

EQUITY	3 Months Ended
	Jun. 30, 2021
EQUITY
NOTE 5 - EQUITY	NOTE 5 – EQUITY Preferred On July 25, 2019, the Company issued 110,000 shares of series A convertible preferred to one entity with a value of $110,000 for cash. Each share of series A preferred is convertible after 180 days to four shares of common stock or at the lowest of: (i) the fixed conversion price; (ii) the equitant of 70% of the lowest closing price for the 20 days prior to the conversion of the preferred shares plus 7% per annum interest. During the three months ended June 30, 2020 the Company issued 1,352,529 shares of common stock for the conversion of 60,000 shares of preferred stock. As of June 30, 2020 the number of preferred shares outstanding was zero. On April 1, 2021, 54,130 shares of preferred stock was converted into 1,968,363 shares of common stock. The conversion eliminated all outstanding convertible preferred shares. Common During the three months ended June 30, 2020 the Company issued 35,715 shares of common stock with a value of $5,000 for settlement of accounts payable. During the three months ended June 30, 2020 the Company issued 677,000 shares of common stock with a value of $85,440 for service. During the three months ended June 30, 2020 the Company issued 1,352,529 shares of common stock for the conversion of 60,000 shares of preferred stock. During the three months ended June 30, 2020 three officers and directors were issued 2,007,000 shares of common stock with a value of $190,915 for service. During the three months period ended June 30, 2020 three officers of the Company converted $1,387,872 of accrued compensation into 13,831,101 shares of common stock of the Company. During the three months ended June 30, 2021 three officers and directors were issued 568,719 shares of common stock with a value of $59,716 for service. During the three months period ended June 30, 2021 a director of the Company converted $23,332 of accrued compensation into 307,010 shares of common stock of the Company. During the three months ended June 30, 2021 the Company issued 50,000 shares of common stock with a value of $5,250 for service.

OPTIONS

OPTIONS	3 Months Ended
	Jun. 30, 2021
OPTIONS
NOTE 6 - OPTIONS	NOTE 6 – OPTIONS As of June 30, 2021, there was no option expenses recognized by the Company and the balance of unrecognized option expense was zero. The following sets forth the options granted and outstanding during the three months ended June 30, 2021: Options Weighted Average Exercise Price Weighted Average Remaining Contract Life Number of Options Exercisable Intrinsic Value Outstanding at March 31, 2021 1,405,000 $ 0.34 4.80 1,405,000 $ - Granted - - - - - Exercised - - - - - Outstanding at June 30, 2021 1,405,000 $ 0.34 4.55 1,405,000 $ - The weighted average remaining life and intrinsic value of the options as of June 30, 2021, was 4.55 years and zero, respectively.

WARRANTS

WARRANTS	3 Months Ended
	Jun. 30, 2021
WARRANTS
NOTE 7 - WARRANTS	NOTE 7 – WARRANTS During the year ended March 31, 2021, the Company granted 3,700,000 warrants to four entities as part of the issuance of 740,000 Series A convertible preferred shares. The warrants expire in two years from grant date and are convertible into common stock at $0.15 per share. The warrants contain an anti-dilution clause which become effective if any instrument is issued after the warrant issuance is converted into common stock at a price lower than the warrant conversion price. The Company used the Black Scholes Pricing model to estimate the fair value of the warrants as of grant date, using the following key inputs: market prices of the Company’s common stock at dates of grant between $0.08-0.11 per share, conversion price of $0.15, volatility of 312.5%-314.49% and discount rate of 0.14-0.16%. Based on the fair value of the common stock of $437,000 and value of the warrants of $349,605 the fair value of the warrants was calculated to be 41% of the total value or $303,000. During the year ended March 31, 2021 the valuation resulted in a deemed dividend from the down round calculation of $555,000. The weighted average remaining life and intrinsic value of the warrants as of June 30, 2021 was Warrants Weighted Average Exercise Price Weighted Average Remaining Contract Life Intrinsic Value Outstanding at March 31, 2020 - $ 0.00 0.00 $ - Granted 3,700,000 0.15 2.00 - Exercised - - - - Expired - - - - Outstanding at March 31, 2021 3,700,000 $ 0.15 1.35 $ - Granted - - - - Exercised - - - - Expired - - - - Outstanding as of June 30, 2021 3,700,000 $ 0.04 1.10 $ -

CONVERTIBLE DEBT

CONVERTIBLE DEBT	3 Months Ended
	Jun. 30, 2021
CONVERTIBLE DEBT
NOTE 8 - CONVERTIBLE DEBT	NOTE 8 - CONVERTIBLE DEBT On May 7, 2020, The Company issued an 8% $50,000 one year convertible note. The note is convertible into common stock at the lesser of $0.20 per share or 80% of the lowest closing bid five days prior to conversion. On July 7, 2020, $50,000 of the one year convertible note payable was converted into 50,000 shares of series A preferred On October 28, 2020, the Company issued a $138,000 convertible note with an OID of $10,000. The note matures on October 28,2021 and bears interest at 10% per annum. After 180 days the note may be converted into common stock of the Company at $0.04 per share or a 30% discount to the VWAP during the 20 days prior to conversion. The initial derivative was calculated using risk free interest of .18%, volatility of 212% and expected life of .50 years. On April 20,2021 note was paid off with the principal of $138,000, accrued interest of $6,805 and financing costs of $41,400. On November 11, 2020, the Company issued a $82,500 convertible note with an OID of $7,500. The note matures on October 28,2021 and bears fixed interest of 10%. After 180 days the note may be converted into common stock of the Company at a 35% discount to the lowest trading price during the 20 days prior to conversion. On April 22, 2021, the note was paid consisting of principal of $82,500, accrued interest of $8,250 and finance costs of $24,750. On February 16, 2021 , the Company issued a $100,000 convertible note with an OID of $5,000. The note matures on February 16, 2022 and bears fixed interest of 10%. After 180 days the note may be converted into common stock of the Company at a 30% discount to the lowest trading price during the 15 days prior to conversion. The initial derivative was calculated using risk free interest of .18%, volatility of 213% and expected life of 1.00 years.

FAIR VALUE MEASUREMENTS AND DER

FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITIES	3 Months Ended
	Jun. 30, 2021
FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITIES
NOTE 9 - FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITIES	NOTE 9 - FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITIES As defined in (Financial Accounting Standards Board ASC 820), fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilized the market data of similar entities in its industry or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observability of those inputs. FASB ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement). The three levels of the fair value hierarchy are as follows: Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities, and listed equities. Level 2 – Pricing inputs are other than quoted prices in active markets included in level 1, which are either directly or indirectly observable as of the reported date and includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors, and current market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options, and collars. Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value As June 30, 2021, the Company believes the amounts reported for cash, payables, accrued liabilities and amounts due to related parties approximate their fair values due to the nature or duration of these instruments. The following table represents the change in the fair value of the derivative liabilities during the quarter ended June 30, 2021: Level 1 Level 2 Level 3 Fair value of derivative liability as of March 31, 2021 $ - $ - $ 302,156 Change in fair value of the derivative - - (164,582 ) -- -- Balance at June 30, 2021 $ - $ - $ 137,574 The estimated fair value of the derivative liabilities at June 30, 2021 was calculated using the Binomial Lattice pricing model with the following assumptions: Risk-free interest rate .16 % Expected life in years 0.25 Dividend yield 0 % Expected volatility 200.00 %

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Jun. 30, 2021
COMMITMENTS AND CONTINGENCIES
NOTE 10 - COMMITMENTS AND CONTINGENCIES	NOTE 10 –COMMITMENTS AND CONTINGENCIES On September 30, 2016, the Company entered a cell line sales agreement with the product manufacturer. Under the terms of the agreement the Company is obligated to make future payments based on the milestones of its achievements. These future payments may be as followed; 1. $100,000 upon the initiation (first dose/first patient) of the first Phase I clinical trial (or equivalent) of a Product; 2. $225,000 upon the initiation (first dose/first patient) of the first Phase III clinical trial (or equivalent) of a Product 3. $225,000 payable upon the first Biologics License Application approval (or equivalent) of a product. 4. Annual maintenance fee upon completion of phase I manufacturing or the transfer of the cell line from Catalent’s control of $50,000; 5. A contingent sales fee upon first commercial sale of a product of 1% of sales or $150,000 whichever is greater payable quarterly. As of June 30, 2021 $299,960 was due for the annual maintenance fee, first patient dosage of phase 1 plus interest. On March 9, 2020, the Board of Directors of the Company adapted an expense bonus program. Under the program, if an acquisition, merger or change in control is effected, 10% of the value of the transaction will be allocated to pay the expenses of the transaction including but not limited to legal, accounting, transfer fees and other miscellaneous expense. The balance of the fund after expenses will be allocated 20% to directors and 80% to officers and employees of the Company as allocated by the Chief Executive Officer and approved by the Board of Directors.

LICENSE AGREEMENT

LICENSE AGREEMENT	3 Months Ended
	Jun. 30, 2021
LICENSE AGREEMENT
NOTE 11 - LICENSE AGREEMENT	NOTE 11- LICENSE AGREEMENT On March 31, 2021, the Company issued a license agreement for US $5,000,000 to BioRay Pharmaceutical Co, LTD, licensing Pritumumab internationally with the exclusion of North and Central America and the Caribbean Islands. Under the terms of the agreement the Company receives $250,000 upon signing of the agreement plus $750,000 with the start of the phase 1 clinical trials , which started in March 2021. In addition, the Company will receive $750,000 upon the enrollment of the 12th patient or the dosage level of 8.0 mg/kg, whichever is achieved first. Further payment of $2,500,000 will be received when the FDA approves the phase 2 clinical trials and $750,000 when the phase 2 clinical trials begin. Upon commercialization by the Licensee, the Company will receive a 9% royalty on net sales for 20 years.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Jun. 30, 2021
SUBSEQUENT EVENTS
NOTE 12 - SUBSEQUENT EVENTS	NOTE 12 - SUBSEQUENT EVENTS The Company has evaluated subsequent events to determine events occurring after June 30, 2021 through August 11, 2021 that would have a material impact on the Company’s financial results or require disclosure and have determined none exist other than those noted above in this footnote.

BASIS OF PRESENTATION (Policies

BASIS OF PRESENTATION (Policies)	3 Months Ended
	Jun. 30, 2021
BASIS OF PRESENTATION
Recent Accounting Pronouncements	In February 2016, the FASB issued ASU No. 2016-02, Leases. The main provisions of ASU No. 2016-02 require management to recognize lease assets and lease liabilities for all leases. ASU 2016-02 retains a distinction between finance leases and operating leases. The classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria for distinguishing between capital leases and operating leases in the previous release’s guidance. The result of retaining a distinction between finance leases and operating leases is that under the lessee accounting model, the effect of leases in the statement of comprehensive income and the statement of cash flows is largely unchanged from previous U.S. GAAP. The amendments in this ASU are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures.
Basis of Presentation	The Company computes net loss per share in accordance with ASC 260, Earnings per Share We have identified the conversion features of certain of our convertible notes payable as derivatives. We estimate the fair value of the derivatives using the Black-Scholes pricing model. We estimate the fair value of the derivative liabilities at the inception of the financial instruments, at the date of conversions to equity and at each reporting date, recording a derivative liability, debt discount, and a gain or loss on change in derivative liabilities as applicable. These estimates are based on multiple inputs, including the market price of our stock, interest rates, our stock price volatility and variable conversion prices based on market prices as defined in the respective agreements. These inputs are subject to significant changes from period to period and to management's judgment; therefore, the estimated fair value of the derivative liabilities will fluctuate from period to period, and the fluctuation may be material.
Revenue recognition	In April 2016, the FASB issued ASU 2016–10 Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing. The amendments in this Update do not change the core principle of the guidance in Topic 606. Rather, the amendments in this Update clarify the following two aspects of Topic 606: identifying performance obligations and the licensing implementation guidance, while retaining the related principles for those areas. Topic 606 includes implementation guidance on (a) contracts with customers to transfer goods and services in exchange for consideration and (b) determining whether an entity’s promise to grant a license provides a customer with either a right to use the entity’s intellectual property (which is satisfied at a point in time) or a right to access the entity’s intellectual property (which is satisfied over time). The amendments are intended to render more detailed implementation guidance with the expectation to reduce the degree of judgement necessary to comply with Topic 606. ASC Topic 606 prescribes a new five-step model entities should follow in order to recognize revenue in accordance with the core principle. These five steps are: 1. Identify the contract(s) with a customer. 2. Identify the performance obligations in the contract. 3. Determine the transaction price. 4. Allocate the transaction price to the performance obligations in the contract. 5. Recognize revenue when (or as) the entity satisfied the performance obligations. The Company implemented the transition using the modified retrospective method of transition. The funds are not earned on milestones that have not been reached per the contract. Based on the cut off treatment of the recognition of revenue per the milestones specific to the license agreements, the Company has determined that there are no adjustments in the value of the revenue recognized from these contracts. The Company has one revenue stream, which is the milestone payments of the license agreement with BioRay Pharmaceutical which is not earned or billed until the milestone per the agreement is met.
Accounts receivable	Accounts receivable are carried at face value less any provisions for uncollectible amounts. Accounts receivable are receivables from a license agreement. No allowance for bad debt was considered necessary for the three months ended June 30, 2021 and 2020, respectively.
Fair Value of Financial Instruments	The Company’s financial instruments consist of cash and cash equivalents, accounts payable and accrued expenses and shareholder loans. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. Financial assets and liabilities recorded at fair value in our condensed consolidated balance sheets are categorized based upon a fair value hierarchy established by GAAP, which prioritizes the inputs used to measure fair value into the following levels: Level 1– Quoted market prices in active markets for identical assets or liabilities at the measurement date. Level 2– Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable and can be corroborated by observable market data. Level 3– Inputs reflecting management’s best estimates and assumptions of what market participants would use in pricing assets or liabilities at the measurement date. The inputs are unobservable in the market and significant to the valuation of the instruments. A financial instrument’s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The following table summarizes the change in the fair value of the derivative liabilities during the three months ended June 30, 2021: Fair value as of March 31, 2021 $ 302,156 Additions at fair value - Transfers in (out) of Level 3 - Change in fair value (164,582 ) Fair value as of June 30, 2021 $ 137,574

BASIS OF PRESENTATION (Tables)

BASIS OF PRESENTATION (Tables)	3 Months Ended
	Jun. 30, 2021
BASIS OF PRESENTATION (Tables)
Schedule of Summarizes of change in the fair value of the derivative liabilities	Fair value as of March 31, 2021 $ 302,156 Additions at fair value - Transfers in (out) of Level 3 - Change in fair value (164,582 ) Fair value as of June 30, 2021 $ 137,574

RELATED PARTY TRANSACTIONS (Tab

RELATED PARTY TRANSACTIONS (Tables)	3 Months Ended
	Jun. 30, 2021
RELATED PARTY TRANSACTIONS (Tables)
Schedule of shares earned by related party	Officer and Director Fiscal Year Annualized Compensation Being Paid President $ 250,000 Chief Financial Officer $ 180,000 Total $ 430,000
Schedule of annual salary and annual severance amounts	Officer and Director Initial Share Awards Under the Contracts Additional Shares Earned to Maintain Ownership Percentage Total Shares Earned President 1,028,910 7,177,269 8,206,179 Chief Financial Officer 617,346 3,821,223 4,438,569 Total 1,646,256 10,998,492 12,644,748

OPTIONS (Tables)

OPTIONS (Tables)	3 Months Ended
	Jun. 30, 2021
OPTIONS
Schedule of Summary of stock options aoutstanding	Options Weighted Average Exercise Price Weighted Average Remaining Contract Life Number of Options Exercisable Intrinsic Value Outstanding at March 31, 2021 1,405,000 $ 0.34 4.80 1,405,000 $ - Granted - - - - - Exercised - - - - - Outstanding at June 30, 2021 1,405,000 $ 0.34 4.55 1,405,000 $ -

WARRANTS (Tables)

WARRANTS (Tables)	3 Months Ended
	Jun. 30, 2021
WARRANTS
Schedule of Summary of warrants outstanding	Warrants Weighted Average Exercise Price Weighted Average Remaining Contract Life Intrinsic Value Outstanding at March 31, 2020 - $ 0.00 0.00 $ - Granted 3,700,000 0.15 2.00 - Exercised - - - - Expired - - - - Outstanding at March 31, 2021 3,700,000 $ 0.15 1.35 $ - Granted - - - - Exercised - - - - Expired - - - - Outstanding as of June 30, 2021 3,700,000 $ 0.04 1.10 $ -

FAIR VALUE MEASUREMENTS AND D_2

FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITIES (Tables)	3 Months Ended
	Jun. 30, 2021
WARRANTS
Schedule of estimated fair value	Risk-free interest rate .16 % Expected life in years 0.25 Dividend yield 0 % Expected volatility 200.00 %
Schedule of summarize of change in the fair value of the derivative liabilities	Level 1 Level 2 Level 3 Fair value of derivative liability as of March 31, 2021 $ - $ - $ 302,156 Change in fair value of the derivative - - (164,582 ) -- -- Balance at June 30, 2021 $ - $ - $ 137,574

BASIS OF PRESENTATION (Details)

BASIS OF PRESENTATION (Details)	3 Months Ended
	Jun. 30, 2021USD ($)
BASIS OF PRESENTATION
Begnning Balance	$ 302,156
Additions at fair value	0
Transfers in (out) of Level 3	0
Change in fair value	(164,582)
Ending Balance	$ 137,574

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details)	3 Months Ended
	Jun. 30, 2021shares
Initial Share Awards Under the Contracts	1,646,256
Additional Shares Earned to Maintain Ownership Percentage	10,998,492
Total Shares Earned	12,644,748
President [Member]
Initial Share Awards Under the Contracts	1,028,910
Additional Shares Earned to Maintain Ownership Percentage	7,177,269
Total Shares Earned	8,206,179
Chief Financial Officer [Member]
Initial Share Awards Under the Contracts	617,346
Additional Shares Earned to Maintain Ownership Percentage	3,821,223
Total Shares Earned	4,438,569

RELATED PARTY TRANSACTIONS (D_2

RELATED PARTY TRANSACTIONS (Details 1)	12 Months Ended
	Mar. 31, 2021USD ($)
Fiscal Year Annualized Compensation Being Paid	$ 430,000
President [Member]
Fiscal Year Annualized Compensation Being Paid	250,000
Chief Financial Officer [Member]
Fiscal Year Annualized Compensation Being Paid	$ 180,000

RELATED PARTY TRANSACTIONS (D_3

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended
	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2020	Mar. 31, 2021
Due to officers and directors	$ 55,500	$ 55,500		$ 123,217
Common stock shares issued for services, shares	50,000		677,000
Common stock shares issued for services, amount	$ 5,250		$ 85,440
Common stock issued for accrued expenses- related party		$ 23,332	$ 1,387,872
September 1, 2020 [Member]
Officers and directors employment agreement terms, description		Under the terms of the agreements the Company issued shares of common stock to the officers and directors equaling 18% of the outstanding shares of the Company as additional future shares are issued. The officers and directors are entitled to additional future shares so their aggregate ownership percentage remains at 18% of the future outstanding shares of the Company
Three Officers and Director [Member]
Common stock shares issued for services, shares		568,719	2,007,000
Common stock shares issued for services, amount		$ 59,716	$ 190,915
Three Officers and Director [Member] | September 1, 2015 [Member]
Officers and directors employment agreement terms, description		the Company entered five-year employment contracts with three of its officers and directors. One of the officers and director resigned as of September 30, 2020. Under the terms of the agreements the Company issued shares of common stock to the officers and directors equaling 11% of the outstanding shares of the Company as of the date of the contracts. As additional future shares are issued, the officers and directors are entitled to additional shares so their aggregate ownership percentage remains at 11% of the outstanding shares of the Company
Three Officers [Member]
Common stock issued for accrued expenses- related party			$ 1,387,872
Common stock shares iaaued for componsation			13,831,101
Director [Member]
Common stock issued for accrued expenses- related party		$ 23,332
Common stock shares iaaued for componsation		307,010

EQUITY (Details Narrative)

EQUITY (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
	Jul. 25, 2019	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2020	Mar. 31, 2021
Common stock shares issued for services, shares		50,000		677,000
Common stock issued for accounts payable, shares				35,715
Common stock issued for accounts payable			$ 0	$ 5,000
Common shares issued upon conversion of preferred stock, shares				1,352,529
Conversion of preferred stock, shares				60,000
Common stock shares value for services, amount		$ 5,250		$ 85,440
Common stock issued for accrued expenses- related party			$ 23,332	$ 1,387,872
Preferred stock, shares issued		0	0		54,130
Series A Convertible Preferred Stock [Member]
Common shares issued upon conversion of preferred stock, shares				1,352,529
Conversion of preferred stock, shares				60,000
Preferred stock, shares issued	110,000
Conversion description	Each share of series A preferred is convertible after 180 days to four shares of common stock or at the lowest of: (i) the fixed conversion price; (ii) the equitant of 70% of the lowest closing price for the 20 days prior to the conversion of the preferred shares plus 7% per annum interest.
Preferred stock shares, value	$ 110,000
April 1, 2021 [Member]
Common shares issued upon conversion of preferred stock, shares			1,968,363
Conversion of preferred stock, shares			54,130
Three Officers and Director [Member]
Common stock shares issued for services, shares			568,719	2,007,000
Common stock shares value for services, amount			$ 59,716	$ 190,915
Three Officers [Member]
Common stock shares issued for compensation				13,831,101
Common stock issued for accrued expenses- related party				$ 1,387,872
Director [Member]
Common stock shares issued for compensation			307,010
Common stock issued for accrued expenses- related party			$ 23,332

OPTIONS (Details)

OPTIONS (Details) - USD ($)	3 Months Ended	12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021
Options
Number of option exercisable, Beginning	1,405,000
Number of option exercisable, Ending	1,405,000
Weighted average exercise price
Weighted average exercise price, Beginning	$ 0.34
Weighted average exercise price, Granted	0
Weighted average exercise price, Exercised	0
Weighted average exercise price, Ending	$ 0.34
Weighted Average Remaining Contract Life
Weighted Average Remaining Contract life, Beginning	4 years 9 months 18 days
Weighted Average Remaining Contract life, Ending	4 years 6 months 18 days
Number of option exercisable
Outstanding option, Beginning	1,405,000
Outstanding option, Ending	1,405,000
Intrinsic value
Intrinsic value, Beginning	$ 0
Intrinsic value, Granted	0
Intrinsic value, Exercised	0	$ 0
Intrinsic value, Ending	$ 0

OPTIONS (Details Narrative)

OPTIONS (Details Narrative)	3 Months Ended
	Jun. 30, 2021USD ($)
OPTIONS (Details)
Intrinsic value, Ending	$ 0
Weighted average remaining life and intrinsic value	4 years 6 months 18 days

WARRANTS (Details)

WARRANTS (Details) - USD ($)	3 Months Ended	12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021
Number of warrants
Outstanding warrants, Beginning	3,700,000	0
Outstanding warrants, granted	0	3,700,000
Outstanding warrants, Expired	0	0
Outstanding warrants, Exercised	0	0
Outstanding warrants, Ending	3,700,000	3,700,000
Weighted average exercise price
Weighted average exercise price, Beginning	$ 0.15	$ 0
Weighted average exercise price, Granted	0	0.15
Weighted average exercise price, Expired	0	0
Weighted average exercise price, Exercised	0	0
Weighted average exercise price, Ending	$ 0.04	$ 0.15
Weighted Average Remaining Contract Life
Weighted Average Remaining Contract life, Beginning	0 years
Weighted Average Remaining Contract life, Granted		2 years
Weighted Average Remaining Contract life, Ending	1 year 1 month 6 days	1 year 4 months 6 days
Intrinsic value
Intrinsic value, Beginning	$ 0	$ 0
Intrinsic value, Granted	0
Intrinsic value, Exercised	0	0
Intrinsic value, Expired	0	$ 0
Intrinsic value, Ending	$ 0

WARRANTS (Details Narrative)

WARRANTS (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021
Deemed dividend from down round		$ 555,000
Volatility rate	200.00%
Warrant [Member]
Exercise price of warrants	$ 0.15
Fair value of warrants	$ 349,605
Total value of warrant	303,000
Fair value of common stock	$ 437,000
Warrants conversion price	$ 0.15
Warrants descriptions		the Company granted 3,700,000 warrants to four entities as part of the issuance of 740,000 Series A convertible preferred shares.
Maximum [Member] | Warrant [Member]
Exercise price of warrants	$ 0.11
Volatility rate	314.49%
Discount rate	0.16%
Minimum [Member] | Warrant [Member]
Exercise price of warrants	$ 0.08
Volatility rate	312.50%
Discount rate	0.14%

CONVERTIBLE DEBT (Details Narra

CONVERTIBLE DEBT (Details Narrative) - USD ($)	Nov. 11, 2020	Jul. 07, 2020	May 07, 2020	Apr. 20, 2021	Feb. 16, 2021	Oct. 28, 2020	Jun. 30, 2021
Risk free interest rate							0.16%
8% Convertible Note [Member]
Convertible debt			$ 50,000
Conversion price, Description			The note is convertible into common stock at the lesser of $0.20 per share or 80% of the lowest closing bid five days prior to conversion.
Series A Convertible Preferred Stock [Member]
Repayment of debt	$ 82,500			$ 138,000
Accrued interest	8,250					$ 6,805
Financing cost	24,750					41,400
Common stock shares issued upon conversion of debt		50,000
Debt instrument converted amount		$ 50,000
Convertible debt	$ 82,500				$ 100,000	$ 138,000
Conversion price, Description	After 180 days the note may be converted into common stock of the Company at a 35% discount to the lowest trading price during the 20 days prior to conversion.				After 180 days the note may be converted into common stock of the Company at a 30% discount to the lowest trading price during the 15 days prior to conversion. The initial derivative was calculated using risk free interest of .18%, volatility of 213% and expected life of 1.00 years.	After 180 days the note may be converted into common stock of the Company at $0.04 per share or a 30% discount to the VWAP during the 20 days prior to conversion. The initial derivative was calculated using risk free interest of .18%, volatility of 212% and expected life of .50 years
Debt instrument original issue discount	$ 7,500				$ 5,000	$ 10,000
Risk free interest rate	10.00%				10.00%
Debt maturity date	Oct. 28, 2021				Feb. 16, 2022	Oct. 28, 2021
Interest rate						10.00%

FAIR VALUE MEASUREMENTS AND D_3

FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITIES (Details)	3 Months Ended
	Jun. 30, 2021USD ($)
Begnning Balance	$ 302,156
Ending Balance	137,574
Level 1 [Member]
Begnning Balance	0
Change in fair value of the derivative	0
Ending Balance	0
Level 2 [Member]
Begnning Balance	0
Change in fair value of the derivative	0
Ending Balance	0
Level 3 [Member]
Begnning Balance	302,156
Change in fair value of the derivative	(164,582)
Ending Balance	$ 137,574

FAIR VALUE MEASUREMENTS AND D_4

FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITIES (Details 1)	3 Months Ended
	Jun. 30, 2021
LICENSE AGREEMENT
Risk-free interest rate	0.16%
Dividend yield	0.00%
Expected life in years	3 months
Expected volatility	200.00%

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	Mar. 09, 2020	Sep. 30, 2016	Jun. 30, 2021
Merger, description	Under the program, if an acquisition, merger or change in control is effected, 10% of the value of the transaction will be allocated to pay the expenses of the transaction including but not limited to legal, accounting, transfer fees and other miscellaneous expense. The balance of the fund after expenses will be allocated 20% to directors and 80% to officers and employees of the Company as allocated by the Chief Executive Officer and approved by the Board of Directors.
Annual Maintenance			$ 299,960
Investment description		A contingent sales fee upon first commercial sale of a product of 1% of sales or $150,000 whichever is greater payable quarterly.
First BLA [Member]
Future payments		$ 225,000
First Phase III clinical trial [Member]
Future payments		225,000
First Phase I clinical trial [Member]
Future payments		100,000
Annual maintenance fee		$ 50,000

LICENSE AGREEMENT (Details Narr

LICENSE AGREEMENT (Details Narrative) - BioRay Pharmaceutical Co LTD [Member]	1 Months Ended
	Mar. 31, 2021USD ($)
Agreement description	Under the terms of the agreement the Company receives $250,000 upon signing of the agreement plus $750,000 with the start of the phase 1 clinical trials , which started in March 2021. In addition, the Company will receive $750,000 upon the enrollment of the 12th patient or the dosage level of 8.0 mg/kg, whichever is achieved first. Further payment of $2,500,000 will be received when the FDA approves the phase 2 clinical trials and $750,000 when the phase 2 clinical trials begin
Issuance of license agreement	$ 5,000,000
Royalty rate	9.00%
Net sales	20 years